Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative, tranquilizing, and antiemetic effects. It is primarily used as a veterinary tranquilizer, especially in pigs and occasionally in elephants. Its use in humans as an antipsychotic is rare. Azaperone acts mainly as a dopamine receptor antagonist (notably at the D3 dopamine receptor), but also exhibits antihistaminic, anticholinergic, and alpha-adrenergic blocking properties. The drug produces sedation by inhibiting central dopaminergic pathways and may cause hypotension due to its peripheral vasodilatory effects[1][2][5]. It is administered intramuscularly, metabolized hepatically, and has an elimination half-life of about 4 hours[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azaperone.